The Net Clinical Benefit of Rivaroxaban for Patients With Acute Coronary Syndrome
| Autor: | Lang Li, Wen-Qin Guo, Zi-Liang Ye |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Acute coronary syndrome Rivaroxaban business.industry Antagonist Hemorrhage 030204 cardiovascular system & hematology medicine.disease Placebo 03 medical and health sciences 0302 clinical medicine Internal medicine Cardiology medicine Humans In patient 030212 general & internal medicine Acute Coronary Syndrome Cardiology and Cardiovascular Medicine business Factor Xa Inhibitors medicine.drug |
| Zdroj: | Journal of the American College of Cardiology. 72:2411-2412 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/j.jacc.2018.07.101 |
| Popis: | Gibson et al. [(1)][1] reported that 2.5-mg twice-daily rivaroxaban was associated with a net reduction in fatal or irreversible events compared with placebo in patients with acute coronary syndrome (ACS). Notably, we have some concerns. First, the benefit of non–vitamin K antagonist oral |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|